Search

SWG Educational Activities

SWG meeting, EHA2023 CongressGuidelines SessionSession title‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

Travel Grants

Travel grant application is now open Apply here

Travel grants are intended to support young investigators to participate in the 7th European CAR T-cell Meeting; therefore, applicants should be 40 years of age or younger.

Read more

EHA Blood Cancer Awareness Month Wrap-up

The first European Hematology Association (EHA) Blood Cancer Awareness Month digital campaign aimed to raise awareness of hematological malignancies and EHA’s commitment “towards a cure for all blood disorders”.

Read more

Highlights of Past EHA (HOPE) Latin America (LA) 2019

Dates: October 4-5, 2019
Location: Mendoza, Argentina
Chairs: 
Prof Dorotea Fantl, President, Sociedad Argentina de Hematología (SAH)
Prof Marivi Mateos, EHA Executive Board Member, European Hematology Association (EHA)

EHA, in partnership with the Sociedad Argentina de Hematología (SAH), is bringing the key messages from the…

Read more

For mentors

When discussing this career development opportunity with your associates, please keep in mind that applicants with the same mentor are eligible to apply. However, no more than ONE participant from a specific mentor will be selected.

Read more

Publications

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
Thomas Chatzikonstantinou; Lydia Scarfò; Georgios Karakatsoulis; Eva Minga; Dimitra Chamou; Gloria Iacoboni; Jana Kotaskova; Christos Demosthenous; Lukas Smolej;…

Read more

EHA-SPSHTM joint membership

Save up to €75 by becoming a joint member of EHA and the Scientific and Practical Society of Hematologists and Transfusiologists from the Republic of Moldova.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more